Hospitals Segment to Dominate Europe Latent TB Detection Market During 2020–2027
According to The Insight Partners market research study on “Europe Latent TB Detection Market to 2027 – COVID-19 Impact and Regional Analysis and Forecast by Test and End User” is expected to reach US$ 420.88 million by 2027 from US$ 304.39 million in 2020. The market is estimated to grow at a CAGR of 4.7% from 2020 to 2027. The report provides trends prevailing in the Europe latent TB detection market along with the drivers and restraints pertaining to the market growth. Rising government initiatives to promote tuberculosis detection and increasing prevalence of tuberculosis are the major factor driving the growth of the Europe latent TB detection market. However, existence of multidrug resistant tuberculosis (MDR-TB) hinders the growth of Europe latent TB detection market.
In case of COVID-19, Europe is highly affected specially France followed by Spain, Italy, and Germany. The European economy is severely affected due to the exponential growth of COVID-19 cases in the region. Countries across Europe are witnessing a resurgence in COVID-19 cases after successfully mitigating outbreaks early in the year. Many countries are declaring more cases each day now than they were during the first wave earlier this year. Lockdowns are being reintroduced in UK, Spain and Italy, and Ireland, as per the European Centre for Disease Prevention and Control (ECDC). Due to the second wave of COVID-19 cases, the government of many countries is working towards scaling up testing capacity, which is restricting the growth of the market. The COVID-19 pandemic and associated response have impacted healthcare services globally, severely disrupting care for many communicable diseases such as tuberculosis TB. Laboratory diagnostic services, considered a cornerstone of any country's capacity to manage TB, are likely to be severely impacted by the COVID-19 pandemic due to re-allocation of resources. In England, compared with 2019, TB notifications decreased by 16.5% during April and by 37.3% during May 2020; the LTBI program was paused in response to COVID-19 in March.
The Europe latent TB detection market has been segmented into the test, end user, and country. Based on test, the market has been segmented into tuberculin skin test (TST) and interferon gamma released assay (IGRA). The interferon gamma released assay (IGRA) segment dominated the Europe latent TB detection market in 2019 and same segment is expected to be fastest growing during forecast period. Based on end user, the market has been segmented into the hospitals, diagnostic centers, laboratories, and others. The hospitals segment dominated the Europe latent TB detection market in 2019 and same segment is expected to be fastest growing during forecast period. Based on country, the market has been segmented into the UK, Germany, France, Italy, Spain, and rest of Europe.
Abbott; ARKRAY, Inc.; BD; bioMerieux SA; F. HOFFMANN-LA ROCHE LTD.; Lionex GmbH; Oxford Immunotec Ltd; QIAGEN; and Serum Institute of India Pvt. Ltd. are among the leading companies in the Europe latent TB detection market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2020, The Oxford Immunotec Ltd has successfully obtained re-registration of the T-SPOT.TB test in China. The re-registration was granted by the Chinese National Medical Products Administration (NMPA).
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com